Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Active Biotech in licensing deal regarding ANYARA
Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

 Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

 EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025

Vinge has advised Qlik in connection with acquisition

 Vinge has advised the Qlik Group in connection with its acquisition of the Qloud Cover Migration technology from Stretch Qonnect. This automated solution, to be branded as the Qlik Analytics Migration Tool, eliminates the complexity of migrating from QlikView, Qlik Sense, and NPrinting to Qlik Cloud – a persistent barrier to cloud adoption.
May 13, 2025